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Abstract
Background: Outcomes for hospitalized patients with tuberculous pleurisy (TP) have rarely been reported, and
whether or not pulmonary involvement affects outcomes is uncertain. This study aimed to analyze the in-hospital
mortality rate of culture-confirmed TP with an emphasis on the clinical impact of pulmonary involvement.
Methods: Patients who were hospitalized for pleural effusion (PE) of unconfirmed diagnosis and finally diagnosed
as TP were identified. We classified them according to the disease extent: isolated pleurisy (isolated pleurisy group)
and pleurisy with pulmonary involvement (pleuro-pulmonary group).
Results: Among the 205 patients hospitalized before the diagnosis was established, 51 (24.9%) belonged to the
isolated pleurisy group. Compared to the pleuro-pulmonary group, patients in the isolated pleurisy group were
younger, had fewer underlying co-morbidities, and presented more frequently with fever and chest pain. Fewer
patients in the isolated pleurisy group had hypoalbuminemia (< 3.5 g/dL) and anemia. The two groups were
similar with regards to PE analysis, resistance pattern, and timing of anti-tuberculous treatment. Patients who had a
typical pathology of TP on pleural biopsy received anti-tuberculous treatment earlier than those who did not, and
were all alive at discharge. The isolated pleurisy group had a lower in-hospital mortality rate, a shorter length of
hospital stay and better short-term survival. In addition, the presence of underlying comorbidities and not receiving
anti-tuberculous treatment were associated with a higher in-hospital mortality rate.
Conclusion: In culture-confirmed tuberculous pleurisy, those with pulmonary involvement were associated with a
higher in-hospital mortality rate. A typical pathology for TP on pleura biopsy was associated with a better outcome.
Background
Tuberculosis (TB) remains a global health problem even
though it has nearly been eradicated in some developed
countries [1,2]. The incidence in 2005 was 76 per
100,000 persons in Taiwan, 80 per 100,000 in the
Republic of Korea, and 600 per 100000 in South Africa
[3,4]. TB remains a leading cause of mortality in many
countries. The mortality rate has been reported to be
6% in those with pulmonary TB, and as high as 31% in
those with disseminated TB [3,4].
Because of variable manifestations and the difficulty in
collecting clinical samples, extra-pulmonary TB is
usually difficult to diagnose early [5]. Tuberculous
pleurisy (TP) is the second most common extra-
pulmonary infection [5], and accounts for approximately
5% of all forms of TB [6]. The gold standard for the
diagnosis of TP is still mycobacterial culture of pleural
effusion (PE), pleura tissue and respiratory specimens,
which requires weeks to yield. The treatment could thus
be delayed, resulting in an increased mortality rate [7].
For those requiring hospitalization, the mortality rate is
further increasing due to increasingly severe infections
and weaker host states [8,9].
The prognostic factors for hospitalized patients with
TP are unclear. Only limited information is available on
w h e t h e ro rn o tp u l m o n a r yi n v o l v e m e n th a san e g a t i v e
prognostic impact [6,10]. However, the mortality rate is
high in tuberculosis patients if they are not promptly
diagnosed and treated [11]. Therefore, we conducted
this retrospective study to investigate the in-hospital
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Methods
Subjects of study
This retrospective study was conducted in a tertiary-care
referral center in northern Taiwan by reviewing the medi-
cal charts as in our previous study [12]. The study was
approved by the Institutional Review Board of the
Research Ethics Committee of National Taiwan University
Hospital (No.: 200809076R). The informed consent was
deemed unnecessary for this retrospective study. We
reviewed the mycobacterial laboratory registry database of
the hospital and identified all patients with PE specimens
sent for mycobacterial culture from January 2001 to
December 2008. Among them, those who were hospita-
lized for PE before the diagnosis of TP was established by
mycobacterial culture for PE were included for further
investigation. Patients were classified into two groups
according to the disease extent of TB: the isolated pleurisy
group and pleuro-pulmonary group. The former was
considered if all respiratory samples from a patient were
culture-negative for Mt u b e r c u l o s i sand there were no pul-
monary parenchymal lesions compatible with active TB on
chest radiographs, defined as new patch(es) of consolida-
tion, collapse, lymphadenopathy, mass or nodule, cavitary
lesion or infiltrate without other proven etiology [13]. The
others were classified into the pleuro-pulmonary group.
Data collection
Patient data were collected by reviewing medical records
and recorded in a standardized case report form by one
chest physician, then verified by another physician from
July 2009 to December 2009. Data included age, gender,
underlying co-morbidities, initial symptoms, laboratory
data and radiographic findings when the index PE sam-
ple was collected, as well as the course and outcome of
anti-tuberculous treatment. Mycobacterial culture and
susceptibility testing were performed according to stan-
dard procedures [3,14]. In our hospital, acid-fast smear
and mycobacterial culture for pleural effusion samples
were routinely performed in cases of lymphocytic
pleural exudate by Light’s criteria [15]. For patients with
adequate cough power, sputum samples were collected
by spontaneous expectoration after explanation without
supervision. For the others, sputum samples were col-
lected by a nurse using a suction tube inserted through
mouth or nasal cavity. We routinely ordered at least
three sets of mycobacterial cultures for sputum samples
collected from each patient. Bilateral lesions were con-
sidered if the contra-lateral lung or pleural cavity were
involved. Three histological findings of pleura tissue
were considered typical for TP: (1) granulomatous
inflammation, (2) caseous necrosis, and (3) the presence
of acid fast bacilli [16].
Patients received standard short-course anti-TB treat-
ment with isoniazid (INH), rifampicin (RIF), ethambutol
(EMB) and pyrazinamide (PZA) for the initial 2 months,
and INH plus RIF for the following 4 months. The stan-
dard regimen was modified if drug resistance or adverse
effects were encountered [17,18]. Patients were followed
for at least 6 months after the index PE samples were
collected, or until death or loss of follow-up. Residual
pleural thickening (RPT) on radiographs after 6 months
of treatment was defined as minor if the pleural thick-
ness was less than 10 mm, or major if equal to or
greater than 10 mm. One pulmonologist and one radiol-
ogist, both blinded to the clinical data, interpreted the
chest radiographs. If their opinions differed, the films
were further reviewed by another senior pulmonologist
blinded to the results.
Statistics
The inter-group differences were compared by using the
independent t test for numerical variables and the chi-
square test or Fisher’s exact test for categorical variables
as appropriate. Survival curves were generated using the
Kaplan-Meier method and were compared using the
log-rank test. Variables having a significant difference
(p < 0.05) for in-hospital mortality in univariate analysis
were further tested by logistic regression with the for-
ward conditional method.
Results
During the 8-year study period, a total of 496 samples
from 412 patients out of 24,759 PE samples yielded
M. tuberculosis. Among them, 205 patients were hospi-
talized when TP was culture-confirmed. The indications
for hospitalization were intolerant fever or dyspnea in
99, massive and/or loculated PE in 51, prolonged symp-
toms (> 14 days) in 51, and presence of lung mass in
14. Among the 205 patients, 51 were further classified
into the isolated pleurisy group. The other 154, includ-
ing 97 (63%) whose sputum samples were culture-
positive for M. tuberculosis, were classified into the
pleuro-pulmonary group. A total of 3,112 patients had
culture-confirmed pulmonary TB.
The clinical characteristics of the patients with TP are
listed in Table 1. Patients in the isolated pleurisy group
were younger and less frequently had underlying co-
morbid illnesses than those in the pleuro-pulmonary
group. Among patients aged less than 65 years, underly-
ing co-morbid illnesses were still less common in the
isolated pleurisy group (11% vs.4 5 % ,p = 0.003), but
similar between the two groups in those aged 65 years
or older (48% vs.4 7 % ,p = 0.968). Malignancy and dia-
betes mellitus were the most common co-morbidities in
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ciency Virus (HIV) was tested in 63 (31%) patients and
was positive in 6, with no inter-group difference. Of the
142 patients with unknown HIV serostatus, all were free
of other acquired immunodeficiency syndrome (AIDS)-
defined illness during follow-up. Male predominance
was noted in both groups. The duration of symptoms
was about 17 days, and 51% of the patients in the iso-
lated TP group presented with fever. Fever was also
more common in those aged less than 65 years (54% vs.
23%, p < 0.001), without underlying co-morbidities (40%
vs. 24%, p = 0.017), or without hypoalbuminemia
(defined as a serum level of albumin less than 3.5 g/dL)
(42% vs. 26%, p = 0.049). More patients in the isolated
pleurisy group suffered from chest pain, but dyspnea
was most common in the pleuro-pulmonary group.
The results of laboratory tests revealed that more
patients in the pleuro-pulmonary group had anemia and
hypoalbuminemia (Table 2). The two findings were also
significantly associated with an age of 65 years or older
(p =0 . 0 0 8a n dp < 0.001, respectively) and underlying
comorbid condition (p < 0.001 for both). Pleural biopsy
was performed in 69% (n = 35) of the isolated pleurisy
group and in 33% (n = 51) of the pleuro-pulmonary
group, with 75.6% (n = 65) showing granulomatous
inflammation with/without caseating changes. Patients
with a typical pleural pathology were treated earlier
after index PE culture than those who did not have a
typical pleural pathology (8.0 vs.1 4 . 6d a y s ,p <0 . 0 0 1 ) .
The resistance patterns were similar between the
isolated pleurisy group and pleuro-pulmonary group.
Nineteen patients had resistance against at least one
first-line drug, and four patients had multidrug-resistant
TB. Radiographically, the isolated pleurisy group had
fewer patients with bilateral lesions and more with locu-
lated PE.
A total of 29 patients did not receive anti-tuberculous
treatment (Table 3). Of them, 19 patients in the pleuro-
pulmonary group died before the diagnosis of TP was
culture-confirmed. Another five in the pleuro-pulmon-
ary group and five in the isolated pleurisy group were
discharged and lost to follow-up before the results of
mycobacterial culture became available. Among those
who received anti-tuberculous treatment, the median
interval from the sampling date of index PE specimen to
anti-tuberculous treatment was 6 days in the isolated
pleurisy group and 9 days in the pleuro-pulmonary
group (p = 0.367) (Table 3). About two-thirds of each
group received anti-tuberculous treatment within
2 weeks after the index PE samples were collected. Nine
patients underwent video-assisted thoracoscopy for dec-
ortication and 19 received tube thoracostomy. There
was no significant between-group difference.
Outcome analysis showed that the pleuro-pulmonary
group had a higher in-hospital mortality rate and longer
length of hospital stay than the isolated pleurisy group
(Table 3). Among the 39 patients who died before dis-
charge, 2 patients belonged to the isolated pleurisy group
and both had underlying malignancy. The remaining 37
patients had pleuro-pulmonary TB. Among them, 24 (65%)
Table 1 Clinical characteristics of the patients with tuberculous pleurisy
Isolated pleurisy group (N = 51) Pleuro-pulmonary group (N = 154) p value
Age (years) 52.6 [27.7] 70.4 [16.5] < 0.001
Age ≥ 65 years 23 (43%) 114 (74%) < 0.001
Male gender 35 (69%) 114 (74%) 0.453
Underlying co-morbid condition* 14 (27%) 72 (47%) 0.015
Diabetes mellitus 4 (8%) 27 (18%) 0.118
Malignancy 7 (14%) 22 (14%) 0.921
Renal failure 3 (6%) 16 (10%) 0.575
Cirrhosis of liver 2 (4%) 7 (5%) 1.000
Autoimmune diseases 0 7 (5%) 0.198
Acquired immunodeficiency syndrome
# 1 (2%) 5 (3%) 1.000
Symptoms
Duration, days 17.8 [31.0] 17.3 [27.4] 0.923
Cough 2 (4%) 19 (12%) 0.112
Fever 26 (51%) 43 (28%) 0.002
Dyspnea 13 (25%) 51 (33%) 0.360
Chest pain 6 (12%) 3 (2%) 0.007
Others† 4 (8%) 38 (25%) 0.010
Data are no. (%) or mean [SD].
* Three and twelve in the isolated pleurisy group and pleuro-pulmonary group, respectively, had two underlying co-morbid conditions.
† Other symptoms included gastrointestinal symptoms, consciousness change and other non-specific symptoms.
# 63 patients received human immunodeficiency tests.
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12, diabetes mellitus in 6, end-stage renal disease in 6, liver
cirrhosis in 4, and autoimmune disease requiring immuno-
suppressant in 1 (5 of them had two underlying diseases).
None of the 39 patients had HIV infection. The cause of
death was multi-organ failure in 28, refractory respiratory
failure in 10, and massive gastrointestinal bleeding in 1.
Among those who died of multi-organ failure, only three
were documented to have concomitant bacteremia or fun-
gemia. The role of pleuro-pulmonary involvement contin-
ued in 2-month survival analysis (Figure 1, p =0 . 0 0 3 ) .
W i t h i nt h ef i r s t6m o n t h so ft r e a t m e n t ,6 7p a t i e n t sd i e d
and 30 were lost to follow-up. Of the remaining 108
patients, 35 of the 36 patients in the isolated pleurisy group
Table 2 Laboratory and radiographic findings of the patients with tuberculous pleurisy
Isolated pleurisy group (N = 51) Pleuro-pulmonary group(N = 154) p value
Positive AFB in PE 1 (2%) 4 (8%) 1.000
Receiving pleura biopsy 35 (69%) 51 (33%) < 0.001
Granulomatous inflammation 25 (71%) 40 (78%) 0.458
Pretreatment resistance pattern
Anyone-drug resistance 5 (10%) 14 (9%) 0.837
Isoniazid 4 (8%) 13 (8%) 0.931
Rifampicin 1 (2%) 3 (2%) 0.977
Ethambutol 2 (4%) 4 (3%) 0.605
Multidrug resistance 1 (2%) 3 (2%) 0.977
Radiographic findings
Bilateral lesions 5 (10%) 61 (40%) < 0.001
Loculated PE 22 (43%) 23 (15%) < 0.001
PE analysis
Leukocyte (/μL) 3016 [5297] 1938 [4649] 0.239
Lymphocyte (%) 82 [24] 75 [25] 0.092
Neutrophil (%) 11 [18] 17 [21] 0.096
Total protein (g/dL) 4.6 [1.0] 4.2 [3.1] 0.264
Lactate dehydrogenase (U/L) 965 [593] 1166 [1837] 0.292
Glucose (mg/dL) 87 [42] 104 [62] 0.202
Blood tests
Leukocyte > 11000 or < 4000/μL 6 (12%) 29 (19%) 0.286
Anemia 21 (41%) 98 (60%) 0.003
Albumin < 3.5 g/dL 19 (37%) 83 (54%) 0.007
Total bilirubin > 1.2 mg/dL 5 (10%) 20 (13%) 0.800
AFB = acid-fast bacilli, PE = pleural effusion.
Data are no. (%) or mean [SD].
* Hemoglobin < 12 g/dL in men or < 11 g/dL in women was considered anemia.
Table 3 Treatment and outcomes
Isolated pleurisy group (N = 51) Pleuro-pulmonary group (N = 154) p value
Anti-tuberculous treatment 46 (90%) 130 (84%) 0.305
Tube thoracostomy or decortication 4 (8%) 24 (16%) 0.163
Days-to-treatment 6 [26.8] 9 [15.6] 0.367
Within 2 weeks 35 (69%) 86 (56%) 0.264
More than 2 weeks 11 (21%) 44 (28%)
Not treated 5 (10%) 24 (16%)
Residual pleura thickening*
≥ 10 mm 10 (29%) 24 (35%) 0.542
< 10 mm 25 (71%) 45 (65%)
In-hospital mortality rate 2 (4%) 37 (24%) 0.001
Length of hospital stay: days 22 [20.8] 33 [27.9] 0.003
Data are no. (%) or mean [SD].
* After six months of anti-tuberculous treatment, only 36 patients in the isolated pleurisy group and 72 in the pleuro-pulmonary group were still being followed
in our hospital.
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received chest radiography after six months. The propor-
tion of patients with RPT ≥ 10 mm was similar in the two
groups (p =0 . 5 4 2 ) .
The 65 patients with typical pleura pathology for TP
were all alive at the time of discharge, whereas only 101
patients (72%) of the remaining 140 patients were alive
at discharge (p < 0.001 by the chi-square test). Thus, we
concluded that “typical pleura pathology” was a signifi-
cant predictor of in-hospital mortality, and then
excluded the 65 patients from multivariate logistic
regression analysis. The results showed that pulmonary
involvement, underlying comorbidity and not receiving
anti-TB treatment were independent risk factors of in-
hospital mortality (Table 4).
Discussion
The pleural cavity is a common site of involvement in
extra-pulmonary TB [5,16]; however, the outcomes and
prognostic factors are unclear in hospitalized popula-
tions. In this retrospective study, those with pleuro-
pulmonary TP accounted for three-fourths of all TP
patients requiring hospitalization and had a higher in-
hospital mortality rate. The in-hospital mortality rate
was also higher among patients who had underlying
comorbidities, did not receive anti-TB treatment and
had no typical pleural pathology for TP.
Although the residual RPT was similar, our analysis
showed that the in-hospital mortality rate was six-fold
higher in patients with pulmonary involvement than
those with isolated pleurisy (24% vs.4 % ) .C o m p a t i b l e
with a previous report showing high mortality in
hospitalized TB patients [8], our previous study revealed
that patients with neutrophil-predominant TP had an
in-hospital mortality rate of 36% [7]. There are several
possible explanations for the high in-hospital mortality
rate of patients with TP, especially for those with pul-
monary involvement. Because patients with isolated
pleurisy are more likely to have local and systemic
inflammatory symptoms such as chest pain and fever
rather than hypoalbuminemia, pulmonary involvement
probably represents an extensive and serious infection
in a compromised and malnourished host. Another pos-
sible explanation is that TB is usually at the top of the
list of the differential diagnoses for lymphocyte-rich
pleurisy [15], whereas it accounts for only 1~2% of the
etiologies for pneumonia [19], thus treatment is fre-
quently delayed. Although a delay in treatment for more
than 14 days was not an independent poor prognostic
factor, the 19 cases of rapid mortality in our study sug-
gest that TP could be an immediately fatal disease, and
timely and effective anti-tuberculous treatment is vital,
especially for those with pleuro-pulmonary involvement.
Figure 1 Survival curves were plotted using the Kaplan-Meier
method for patients with tuberculous pleurisy according to
the disease extent (the isolated pleurisy group and pleuro-
pulmonary group). Black dots represent patients who were still
alive at the end of the study.
Table 4 Factors possibly associated with in-hospital
mortality
Characteristics Unlvariate
p value
Multivariate
p value
Multivariate
OR (95% CI.)
Age ≥ 65 years 0.025 0.865
< 65 years
Underlying co-
morbid illness
Yes 0.001 0.036 2.60
(1.06~6.38)
No
Disease extent Pleuro-
pulmonary
0.001 0.014 8.67
(1.56~48.27)
Isolated
pleurisy
Serum albumin
level
< 3.5 g/dL < 0.001 0.344
≥ 3.5 g/dL
Anemia Presence 0.008 0.444
Absence
Drug resistance Anyone 0.370
All
sensitive
Radiographic
finding
Bilateral 0.002 0.211
Unilateral
Days to anti-
tuberculous
treatment
No
treated
< 0.001 < 0.001 12.17
(3.88~38.14)
> 14 days 0.164 0.914 1.06
(0.38~2.92)
≤ 14 days
The 65 patients with typical pleural pathology for TP were all alive at
discharge, whereas 39 of the remaining 140 patients died in hospital (p <
0.001 by the chi-square test). Therefore, logistic regression was performed on
the 140 patients who had not received a pleural biopsy or had no typical
pleural pathology for TP.
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difference in clinical outcomes between isolated TP and
pleuro-pulmonary TB [6,10]. Again there are several
possible explanations. First, the previous studies ana-
lyzed survival after completing anti-TB treatment and
relapse, rather than in-hospital mortality. These long-
term outcomes were more likely to be confounded by
other factors, such as age, underlying co-morbidity, and
socioeconomic status. Second, those needing admission
were probably more severe cases, especially in a referral
medical center. Finally, the patients in the previous
reports were younger, around the fifth to early sixth
decade, and less than 10% of them had underlying
comorbid conditions [16,20].
Our results revealed that histologic examination of the
pleural biopsy is the key step for the early diagnosis of
TP, because it can effectively demonstrate a typical
pathology of TP in more than three-fourths of patients
within 3 days, which is higher than the yield rate of
mycobacterial cultures for PE samples (11%) [21]. More-
over, even when using the fluorometric BACTEC tech-
nique, the results of mycobacterial culture still take one
to two weeks [22]. Hence, a typical pleura pathology
c o u l dr e s u l ti nt h ee a r l yd i a g n o s eo fT Pa n di m p r o v e d
outcomes. Therefore, for in-patients with lymphocyte-
rich PE, the possibility of tuberculosis should be kept in
mind and pleural histology should be performed at an
early stage if clinically feasible. For the early diagnosis of
TP, biomarkers in pleural effusion such as adenosine
deaminase and interferon-gamma have been shown to
be helpful, but further investigations are needed for the
application of nucleic acid amplification tests and inter-
feron-gamma release assays [23,24].
Our study has several limitations. First, in this retro-
spective study, the number of patients with culture-
confirmed TP could have been underestimated because
mycobacterial cultures were not routinely performed for
every PE sample, and most studies show the sensitivity
to be less than 30% [16]. Therefore, the patients with
culture-negative TP might have been missed. However,
the selected patients were all true cases of TP and
represented a homogenous population for detailed ana-
lysis. Second, the 6-month follow-up rate was less than
90%. Third, our study population was selected from a
large medical referral center. Whether our findings can
be extrapolated to all TP patients should be further
confirmed.
Conclusion
Our study revealed that for hospitalized patients with
TP, pulmonary involvement, underlying comorbidities,
no typical pleura pathology and not receiving anti-TB
treatment were associated with a worse in-hospital out-
come. Aggressive examination, such as pleural biopsy,
for pleural effusion with unknown cause is suggested for
the early diagnosis and treatment if clinically
appropriate.
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